Content continues after advertisement

Leptospirosis Antibody Titers & Vaccination

Clinician's Brief (Capsule)

Preventive Medicine

|February 2016

Sign in to Print/View PDF

This prospective study sought to determine the antibody response of dogs to commercially available quadrivalent Leptospira vaccines containing the serovars canicola, grippotyphosa, icterohemorragiae, and pomona. Healthy client-owned dogs (n = 32) with known vaccination history and no Leptospira spp vaccination in the previous year were randomly assigned to receive 1 of the 4 commercially available quadrivalent vaccines at weeks 0 and 3. Booster vaccines were given to 25/32 dogs at week 52. Antibody titers to serovars bratislava, canicola, grippotyphosa, hardjo, icterohemorrhagiae, and pomona were determined by microscopic agglutination test (MAT) on weeks 0, 3, 4, 7, 15, 29, 52, and 56. MAT titers ≥1:100 were considered positive. 

Highly variable antibody responses were detected between and within vaccine groups. Highest MAT titers (≥1:800) were detected at weeks 4 and 56. However, most dogs were seronegative for many serovars by week 15, and most were seronegative for all serovars at week 52. At week 56, only canicola was associated with MAT titers >1:100 in >50% of dogs, regardless of vaccine. Some dogs developed positive MAT titers to bratislava or hardjo, which were not contained in the vaccines. Previous challenge studies have demonstrated duration of immunity for commercial Leptospira vaccines to be ≥1 year, with vaccinated dogs protected from clinical disease and renal carrier state for 12 or 14 months, suggesting that MAT titers are not well-correlated with duration of immunity of vaccines against natural infection. Furthermore, MAT titers have poor specificity for distinguishing vaccinal titers from natural infection. Study funded by IDEXX Laboratories.

Commentary

Leptospirosis diagnosis can be challenging because of our reliance on antibody titers. Intrinsically, antibody titers can (and should) be affected by vaccination. This paper aims to examine the MAT titers that result from vaccination. Unfortunately, because of study design, there are some shortcomings to this paper. It is unclear which dogs included in this population were vaccinated in the past (and whether that affected their titers). Also, 4 different vaccines were used in this relatively small sample size (n = 32), limiting our ability to discern intervaccine variability. Despite a small sample size, the paper was able to show marked MAT response to most serovars after initial booster vaccines.—Jonathan Dear, DVM, DACVIM

References

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

All Clinician's Brief content is reviewed for accuracy at the time of publication. Previously published content may not reflect recent developments in research and practice.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Podcasts

Clinician's Brief:
The Podcast
Listen as host Alyssa Watson, DVM, talks with the authors of your favorite Clinician’s Brief articles. Dig deeper and explore the conversations behind the content here.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2023 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Terms & Conditions | DMCA Copyright | Privacy Policy | Acceptable Use Policy